The General Movements Assessment (GMA) is one of the best predictive assessment tools for infants at risk of adverse outcomes, with excellent inter-observer reliability reported for the preterm infant population. The GMA is now being used with infants post-surgery, however there are no studies reporting on reliability and agreement with this cohort. This information is necessary to determine the validity of the GMA across infant populations.
of Auckland, Liggins Institute Background: Antenatal corticosteroids substantially reduce morbidity related to preterm birth although it remains uncertain whether dexamethasone or betamethasone provides greater benefit. The primary aim of the A*STEROID Trial was to assess whether dexamethasone compared with betamethasone given to women at risk of preterm birth at <34 weeks' gestation increases the chance of their children surviving free of neurosensory disability at 2 years' corrected age.
Methods: Multicentre randomised trial. Women at risk of preterm birth at <34 weeks' gestation with consent were randomised to either 24 mg dexamethasone (dexamethasone sodium phosphate) or 22.8 mg betamethasone (Celestone Chronodose) given in two divided doses 24 hours apart. The primary outcome was death or any neurosensory disability at 2 years' corrected age.
Results: Of the 1346 women recruited, 670 were randomised to receive dexamethasone and 667 to betamethasone. Overall 24.0% of infants had respiratory distress syndrome, 9.4% chronic lung disease and 4.4% intraventricular haemorrhage. At 2 years' corrected age 28.4% had died or had neurosensory disability (cerebral palsy 12.4%, blindness <0.1%, deafness 3.2%, developmental delay 26.3%). The comparisons by treatment group will be presented.
Conclusion:
The A*STEROID Trial results provide new knowledge about the effects of dexamethasone and betamethasone given to women at risk of early preterm birth on important neonatal and early childhood health. The results have implications for clinical practice. Royal Prince Alfred Hospital Background: GBS is a transient bacteria that can colonise the genital tract. At birth, a GBS positive mother has a 36.4% chance of transmission to the newborn. When colonised, the newborn has a 0.25-3% chance of developing early onset GBS disease [EOGBSD] which can be fatal. The Royal Prince Alfred Hospital [RPAH] performs the recommended universal antenatal GBS culture screening (35-37 weeks gestation). This method requires that GBS positive women be offered intrapartum antibiotics prophylacticly. There is level 1 evidence that polymerase chain reaction [PCR] screening is more accurate and faster (<60 minutes). The Xpert GBS is one such PCR method and when compared to intrapartum culture (gold standard) the performance characteristics of Xpert GBS were: sensitivity: 98.5%, specificity: 99.6%, positive predictive value: 97.8%, negative predictive value: 99.7% for detecting intrapartum GBS status.
A LITERATURE REVIEW AND COST ANALYSIS COMPARING EFFECTIVENESS OF TWO GROUP B STREPTOCOCCAL SCREENING METHODS IN TERM PREGNANCIES
Objective: To compare Xpert GBS to the current universal antenatal culture screening.
Design: A cost analysis of GBS screening and related expenses. Participants: Term pregnant women at RPAH (January 2015-January 2016).
Methods: A single-institution study using statistics from CER-NER Millennium and Neonatal Intensive Care Units' Data Collection. Costs of both screening methods as well as the diagnosis and treatment of EOGBSD will be compared, including: antibiotics; bed-days for induction of labour due to GBS-positive women with pre-labour rupture of membranes; and, time wasted administering antibiotics to GBS negative women.
